Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes

Advances in Enzyme Regulation

Volumn 46, Issue 1, 2006, Pages 98-112

  Vyas, Paresh ^a   Sternberg, Alexander ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CYTOLOGY; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

B-LYMPHOCYTES; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 33748138950     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2006.01.019     Document Type: Article

References (69)

1. Adolfsson J., Mansson R., Buza-Vidas N., Hultquist A., Liuba K., Jensen C.T., et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121 (2005) 295-306
2. Aizawa S., Nakano M., Iwase O., Yaguchi M., Hiramoto M., Hoshi H., et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23 (1999) 239-246
3. Akashi K., Traver D., Miyamoto T., and Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404 (2000) 193-197
4. Amin H.M., Jilani I., Estey E.H., Keating M.J., Dey A.L., Manshouri T., et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 102 (2003) 1866-1868
5. Aul C., Germing U., Gattermann N., and Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious?. Leuk Res 22 (1998) 93-100
6. Backx B., Broeders L., Touw I., and Lowenberg B. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 7 (1993) 75-79
7. Beachy P.A., Karhadkar S.S., and Berman D.M. Tissue repair and stem cell renewal in carcinogenesis. Nature 432 (2004) 324-331
8. Benito A.I., Bryant E., Loken M.R., Sale G.E., Nash R.A., John Gass M., et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 27 (2003) 425-436
9. Bennett J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72 (2000) 131-133
10. Bennett J.M., Kouides P.A., and Forman S.J. The myelodysplastic syndromes: morphology, risk assessment, and clinical management. Int J Hematol 76 Suppl 2 (2002) 228-238
11. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
12. Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005.
13. Epperson D.E., Nakamura R., Saunthararajah Y., Melenhorst J., and Barrett A.J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25 (2001) 1075-1083
14. Flores-Figueroa E., Gutierrez-Espindola G., Montesinos J.J., Arana-Trejo R.M., and Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26 (2002) 677-686
15. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103 (1998) 176-188
16. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
17. Harada H., Harada Y., Niimi H., Kyo T., Kimura A., and Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103 (2004) 2316-2324
18. Hirai H., Kobayashi Y., Mano H., Hagiwara K., Maru Y., Omine M., et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 327 (1987) 430-432
19. Holyoake T., Jiang X., Eaves C., and Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999) 2056-2064
20. Holyoake T.L., Jiang X., Jorgensen H.G., Graham S., Alcorn M.J., Laird C., et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97 (2001) 720-728
21. Hope K.J., Jin L., and Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5 (2004) 738-743
22. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351 (2004) 657-667
23. Kibbelaar R.E., van Kamp H., Dreef E.J., de Groot-Swings G., Kluin-Nelemans J.C., Beverstock G.C., et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 79 (1992) 1823-1828
24. Knuutila S. Lineage specificity in haematological neoplasms. Br J Haematol 96 (1997) 2-11
25. Kondo M., Weissman I.L., and Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91 (1997) 661-672
26. LeBien T.W. Fates of human B-cell precursors. Blood 96 (2000) 9-23
27. Lepelley P., Preudhomme C., Vanrumbeke M., Quesnel B., Cosson A., and Fenaux P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 8 (1994) 1342-1349
28. Lopez R.A., Schoetz S., DeAngelis K., O'Neill D., and Bank A. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci USA 99 (2002) 602-607
29. Lyons J., Janssen J.W., Bartram C., Layton M., and Mufti G.J. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 71 (1988) 1707-1712
30. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 95 (1998) 9448-9453
31. Maes B., Meeus P., Michaux L., Bijnens L., Boogaerts M., Hagemeijer A., et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol 10 (1999) 825-829
32. Manz M.G., Miyamoto T., Akashi K., and Weissman I.L. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 99 (2002) 11872-11877
33. Matsutani T., Yoshioka T., Tsuruta Y., Shimamoto T., Ohyashiki J.H., Suzuki R., et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 27 (2003) 305-312
34. McKercher S.R., Torbett B.E., Anderson K.L., Henkel G.W., Vestal D.J., Baribault H., et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. Embo J 15 (1996) 5647-5658
35. Melenhorst J.J., Eniafe R., Follmann D., Nakamura R., Kirby M., and Barrett A.J. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 119 (2002) 97-105
36. Milhem M., Mahmud N., Lavelle D., Araki H., DeSimone J., Saunthararajah Y., et al. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103 (2004) 4102-4110
37. Miura I., Kobayashi Y., Takahashi N., Saitoh K., and Miura A.B. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br J Haematol 110 (2000) 876-879
38. Muller-Sieburg C.E., Cho R.H., Karlsson L., Huang J.F., and Sieburg H.B. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood 103 (2004) 4111-4118
39. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
40. Nakao M., Horiike S., Fukushima-Nakase Y., Nishimura M., Fujita Y., Taniwaki M., et al. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br J Haematol 125 (2004) 709-719
41. Nilsson L., Astrand-Grundstrom I., Anderson K., Arvidsson I., Hokland P., Bryder D., et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100 (2002) 259-267
42. Nilsson L., Astrand-Grundstrom I., Arvidsson I., Jacobsson B., Hellstrom-Lindberg E., Hast R., et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96 (2000) 2012-2021
43. Ogata K., Nakamura K., Yokose N., Tamura H., Tachibana M., Taniguchi O., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100 (2002) 3887-3896
44. Okada M., Okamoto T., Takemoto Y., Kanamaru A., and Kakishita E. Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities. Acta Haematol 102 (2000) 124-130
45. Padua R.A., Carter G., Hughes D., Gow J., Farr C., Oscier D., et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 2 (1988) 503-510
46. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., and Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96 (2000) 3932-3938
47. Plasilova M., Zivny J., Jelinek J., Neuwirtova R., Cermak J., Necas E., et al. Trail (Apo2l) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16 (2002) 67-73
48. Quesnel B., and Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma 35 (1999) 437-443
49. Ramos F., Fernandez-Ferrero S., Suarez D., Barbon M., Rodriguez J.A., Gil S., et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res 23 (1999) 283-290
50. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
51. Ryan D.H., Nuccie B.L., Ritterman I., Liesveld J.L., Abboud C.N., and Insel R.A. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood 89 (1997) 929-940
52. Saitoh K., Miura I., Takahashi N., and Miura A.B. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood 92 (1998) 2886-2892
53. Sato T., Kim S., Selleri C., Young N.S., and Maciejewski J.P. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia 12 (1998) 1187-1194
54. Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100 (2002) 1570-1574
55. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102 (2003) 3025-3027
56. Scott E.W., Simon M.C., Anastasi J., and Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265 (1994) 1573-1577
57. Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L., Dar S., et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20 (1996) 891-900
58. Shizuru J.A., Negrin R.S., and Weissman I.L. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med 56 (2005) 509-538
59. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
60. Steensma D.P., Gibbons R.J., Mesa R.A., Tefferi A., and Higgs D.R. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 74 (2005) 47-53
61. Steensma D.P., and Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 27 (2003) 95-120
62. Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T, et al. Evidence for reduced B-cell progenitors in early (low risk) myelodysplastic syndrome. Blood 2005; Aug 2 [Epub ahead of print].
63. Thanopoulou E., Cashman J., Kakagianne T., Eaves A., Zoumbos N., and Eaves C. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 103 (2004) 4285-4293
64. van Kamp H., Fibbe W.E., Jansen R.P., van der Keur M., de Graaff E., Willemze R., et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 80 (1992) 1774-1780
65. van Lom K., Hagemeijer A., Smit E.M., and Lowenberg B. In situ hybridization on May-Grunwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities. Blood 82 (1993) 884-888
66. Voulgarelis M., Giannouli S., Ritis K., and Tzioufas A.G. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 34 (2004) 690-700
67. Wang W., Matsuo T., Yoshida S., Mori H., Miyazaki Y., Kuriyama K., et al. Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. Leukemia 14 (2000) 1751-1756
68. Warner J.K., Wang J.C., Hope K.J., Jin L., and Dick J.E. Concepts of human leukemic development. Oncogene 23 (2004) 7164-7177
69. Zang D.Y., Goodwin R.G., Loken M.R., Bryant E., and Deeg H.J. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 98 (2001) 3058-3065